· Published by Health Canada · Official notice
Health Canada is advising health professionals and patients regarding the recall of specific lots of Proglycem® Suspension by Schering Canada Inc. due to elevated levels of the active ingredient, Diazoxide. Proglycem® Suspension is an oral liquid medication prescribed by physicians for the treatment of low blood sugars resulting from rare conditions associated with abnormally increased insulin levels. The affected lots of Proglycem® Suspension that are being recalled may cause severe reactions or death as a result of increasing blood sugars above normal ranges.
The affected lots are: 2-GJAB-02, 3-GJAB-01, 3-GJAB-02A.
A letter was sent to health professionals by Schering Canada Inc on June 1, 2004, advising them of this potential problem. As a precaution, Health Canada is advising patients who use this drug to monitor their blood or urine sugars very closely and to contact their physicians for further instructions.
Patients are also advised to be aware of the symptoms from excessively high blood sugars and to contact a health professional immediately if any of these symptoms are experienced. Symptoms of excessively high blood sugars include:
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or
Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
For other inquiries: please refer to contact information.
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.